发展蛋白质组学为基础的乳腺癌诊断学的探索  

Exploration of the Developing Proteomic-based Breast Cancer Diagnostics

作　　者：潘志远[1] 黄耀[1] 

机构地区：[1]广东医学院附属福田医院肝胆甲乳外科,广东深圳518000

出　　处：《医学综述》2013年第19期3515-3518,共4页Medical Recapitulate

摘　　要：在过去的十余年里,多种基因组学和组织学技术加快了新的乳腺癌诊疗模式的发展,对患者进行分子水平诊断和个性化治疗成为今后的发展趋势。与基因组学和组织学技术快速发展相比较,用于指导乳腺癌的筛查和治疗的肿瘤标志物研究进展却微乎其微,尤其是对血清或组织中乳腺癌特异性标志物的检测。该文就基因组学与蛋白质学在乳腺癌分子诊断学应用进展中存在巨大差距的潜在原因,以及改进蛋白质组学研究设计的策略予以综述。Over the past decade, multiple genetic and histological approaches have accelerated develop- ment of new breast cancer diagnostics and treatment paradigms. Molecular level diagnosis and personalized treatment of patients become the development trend in the future. Compared with the rapid advancements in genetic and histological assays for breast cancers, the research progress of tumor marker used to guide breast cancer screening and treatment is minimal, especially in the detection of breast cancer-specific markers in serum or tissue. Here is to make a review of some potential reasons for this large gap in developing protein biomarkers,as well as new strategies for improving proteomics design.

关 键 词：乳腺癌 蛋白质组学 糖蛋白组学 基质辅助激光解析电离飞行时间质谱法 

分 类 号：R604[医药卫生—外科学]